Document is current
Any future updates will be listed below
-
Authors
Post, Kathryn E. https://orcid.org/0000-0002-1777-5158
Dunderdale, Laura
Datta, Shibani
Varella, Leticia
Horick, Nora
Traeger, Lara
Greer, Joseph A.
Moy, Beverly
Temel, Jennifer S.
Jacobs, Jamie M.
-
Funding
Funding for this research was provided by:
Electronic Space Systems Corporation (ESSCO) Massachusetts General Hospital Breast Cancer Research Fund
- License Information
-
More Information
Article History
Received: 12 September 2025
Accepted: 13 October 2025
First Online: 21 November 2025
Declarations
:
: Authors KP, LD, SD, NH, LT, LV, and BM declare that they have no financial interests. Dr. Greer is a consultant for BeOne Medicines, receives research funding from Blue Note Therapeutics, is on the GlaxoSmithKline speakers bureau, and receives royalties from Oxford University Press. Dr. Temel is on the scientific advisory board for ThymeCare. Dr. Jacobs has a financial interest in OncoveryCare (formerly VivorCare, Inc.), a company advancing a virtual survivorship clinic for individuals with cancer. Dr. Jacobs’ interests were reviewed and are managed by MGH and Mass General Brigham in accordance with their conflict of interest policies.
: This study was conducted in accordance with the principles outlined in the Declaration of Helsinki. Approval was granted by the Dana-Farber/Harvard Cancer Center Institutional Review Board (Protocol #22-091; NCT #05465408).
: All individual participants in the study provided informed consent.
